Overview: C-Peptide Fasting TestIntroduction: The C-Peptide Fasting Test measures C-peptide to assess insulin production, helping diagnose diabetes or hypoglycemia, causing fatigue or shakiness. Aligned with 2023 ADA guidelines, it uses an immunoassay for high sensitivity, aiding in endocrine screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in endocrinology for patients with suspected metabolic disorders.
Other Names: C-Peptide Fasting Assay, Insulin Production Test.
FDA Status: Laboratory-developed test (LDT), meeting endocrinology standards for diagnostic accuracy.
Historical Milestone: C-peptide testing began in the 1970s with diabetes research. Immunoassays emerged in the 1980s, and by the 2000s, high-sensitivity assays improved accuracy.
Purpose: Diagnoses diabetes or hypoglycemia, guides treatment, and monitors insulin production in patients with fatigue or shakiness.
Test Parameters: 1. C-Peptide
Pretest Condition: Fasting for 10-12 hours required to stabilize C-peptide levels. Collect serum or plasma after overnight fasting. Report symptoms like fatigue or shakiness, and list medications like insulin.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fatigue, shakiness, or history of diabetes/hypoglycemia. Include current medications, especially insulin or oral hypoglycemics.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for diabetes or hypoglycemia treatment.
Procedural Considerations: Uses an immunoassay to measure C-peptide levels. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Non-fasting samples or insulin therapy may alter results. Hemolysis or improper storage can degrade samples.
Clinical Significance: Low C-peptide levels indicate type 1 diabetes, prompting insulin therapy. High levels suggest insulin resistance or hypoglycemia, requiring further evaluation.
Specialist Consultation: Consult an endocrinologist for result interpretation. A diabetologist referral is advised for complex cases.
Additional Supporting Tests: Fasting glucose test, HbA1c, or insulin level test to confirm diabetes or hypoglycemia.
Test Limitations: Results may be affected by insulin therapy. Clinical correlation is required.
References: ADA Diabetes Guidelines, 2023; Diabetes Care, Skyler JS, 2022.
